Trial Profile
A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2005
Price :
$35
*
At a glance
- Drugs Epratuzumab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 25 Sep 2005 New trial record.